UPS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
United Parcel Service Inc (UPS) is not an optimal buy at this moment for a beginner investor with a long-term strategy. While there are some positive signals such as hedge fund buying and stable financial performance, the stock is currently overbought based on RSI, and analysts have recently lowered price targets, reflecting cautious sentiment. Additionally, there are no strong catalysts or proprietary trading signals to justify immediate action.
The technical indicators show a mixed picture. The MACD is positive and expanding, suggesting bullish momentum. The moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading above key resistance levels. However, the RSI is at 85.85, indicating the stock is overbought, which may limit further upside in the short term.
Hedge funds are significantly increasing their positions in UPS, with buying up 3861.21% over the last quarter.
Stable financial performance in Q4 2025, with net income and EPS showing growth despite a slight revenue decline.
Analysts have recently lowered price targets, reflecting cautious sentiment about UPS's near-term growth prospects.
The stock is currently overbought based on RSI, which could lead to a short-term pullback.
No significant insider or congress trading activity to indicate strong confidence in the stock.
In Q4 2025, UPS reported a revenue decline of -3.25% YoY to $24.48 billion. However, net income increased by 4.07% YoY to $1.79 billion, and EPS rose by 4.48% to $2.1. Gross margin also improved to 79.68%, up 2.99% YoY, indicating operational efficiency.
Analysts have mixed views on UPS. Recent ratings include price target reductions from JPMorgan ($106), Citi ($118), and BofA ($105), reflecting cautious sentiment due to macroeconomic uncertainties and union contract constraints. However, some firms like Jefferies and Bernstein maintain Buy ratings with higher price targets, citing UPS's strong infrastructure and potential for margin improvement in the second half of 2026.
